퓨전 생검 시장 규모, 점유율, 동향 분석 보고서 : 생검 경로별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Fusion Biopsy Market Growth & Trends:

The global fusion biopsy market size is expected to reach USD 1.2 billion by 2030, registering a CAGR of 8.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of prostate cancer, growing demand for targeted biopsy, and the rising utilization rate of multipara metric MRI in prostate cancer care are factors expected to drive the market during the forecast period. Moreover, factors such as rising awareness of the value of routine therapeutic interventions and emerging reimbursement policies are projected to drive demand in the market for fusion biopsy.

The high sensitivity and specificity of targeted fusion biopsy in delineating prostate lesions compared to other traditional technologies such as TRUS biopsy, PSA test, or Digital Rectal Examination is expected to contribute to the market growth. The reliability & reproducibility of the fusion biopsy system in the diagnosis of aggressive tumors is expected to make it a standard tool in prostate biopsy. An increasing number of radiologists gaining expertise in interpreting prostate MRI, coupled with the implementation of standard image grading systems such as PI-RADS and Gleason score, has increased the utilization rate of targeted MR/Ultrasound fusion biopsy systems.

The increasing number of government initiatives in terms of funding research, spreading awareness, and conducting mass screening programs related to prostate cancer are expected to play a crucial in the growth of the market. Some of the growth strategies adopted by market players include partnerships, product launches, participation in trade events and conferences, and acquisitions to drive and sustain growth in this highly competitive space.

Fusion Biopsy Market Report Highlights:

• The transrectal segment held the largest market share in 2024, as it is the gold standard and commonly used method of prostate fusion biopsy
• The transperineal segment is expected to grow at the fastest rate during the forecast period owing to the safety, diagnostic efficiency, and ability to access ventral prostate areas
• The hospital segment accounted for the largest revenue share in 2024, owing to factors such as the increasing procurement rate of MR/US targeted fusion biopsy systems in teaching hospitals
• The diagnostics centers segment is expected to expand at a significant rate over the forecast period. Shorter wait times, cost efficiency, and developing reimbursement paradigm are the factors expected to drive the growth of this segment
• North America held the largest market share in 2024 and is anticipated to maintain its dominance over the forecast period

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Biopsy route
  • 1.1.2. End-use
  • 1.1.3. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
    • 1.3.5.1. Data for Primary Interviews in North America
    • 1.3.5.2. Data for primary interviews in Europe
    • 1.3.5.3. Data for primary interviews in Asia Pacific
    • 1.3.5.4. Data for Primary Interviews in Latin America
    • 1.3.5.5. Data for Primary Interviews in MEA
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.6.2. Volume price analysis (Model 2)
    • 1.6.2.1. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives
  • 1.9.1. Objective 1
  • 1.9.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Biopsy route outlook
  • 2.2.2. End-use outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Fusion Biopsy Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Industry Value Chain Analysis
  • 3.3.1. Reimbursement framework
• 3.4. Market Dynamics
  • 3.4.1. Market Driver Analysis
    • 3.4.1.1. Increasing prevalence of prostate cancer
    • 3.4.1.2. Technological advancements in fusion imaging modalities
    • 3.4.1.3. Increasing funds and investments by public and private sector
  • 3.4.2. Market Restraint Analysis
    • 3.4.2.1. High cost of fusion biopsy system
    • 3.4.2.2. Liquid biopsy system
• 3.5. Fusion Biopsy Market Analysis Tools
  • 3.5.1. Industry Analysis - Porter's
    • 3.5.1.1. Supplier power
    • 3.5.1.2. Buyer power
    • 3.5.1.3. Substitution threat
    • 3.5.1.4. Threat of new entrant
    • 3.5.1.5. Competitive rivalry
  • 3.5.2. PESTEL analysis
    • 3.5.2.1. Political landscape
    • 3.5.2.2. Technological landscape
    • 3.5.2.3. Economic Landscape
  • 3.5.3. Major deals & strategic alliances analysis
  • 3.5.4. Market entry strategies
  • 3.5.5. Covid-19 Impact Analysis

Chapter 4. Fusion Biopsy Market: Biopsy Route Estimates & Trend Analysis

• 4.1. Definitions and Scope
  • 4.1.1. Transrectal
  • 4.1.2. Transperineal
• 4.2. Biopsy Route Market Share, 2024 & 2030
• 4.3. Segment Dashboard
• 4.4. Global Fusion Biopsy Market by Biopsy Route Outlook
• 4.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5.1. Transrectal
    • 4.5.1.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 4.5.2. Transperineal
    • 4.5.2.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)

Chapter 5. Fusion Biopsy Market: End-use Estimates & Trend Analysis

• 5.1. Definitions and Scope
  • 5.1.1. Hospitals
  • 5.1.2. Diagnostic centers
  • 5.1.3. Ambulatory care centers
• 5.2. End-use, 2024 & 2030
• 5.3. Segment Dashboard
• 5.4. Fusion Biopsy Market by End-use Outlook
• 5.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5.1. Hospitals
    • 5.5.1.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 5.5.2. Diagnostic centers
    • 5.5.2.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 5.5.3. Ambulatory care centers
    • 5.5.3.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)

Chapter 6. Fusion Biopsy Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Regional Market Snapshot
• 6.4. Regional Market Share and Leading Players, 2024
  • 6.4.1. North America
  • 6.4.2. Europe
  • 6.4.3. Asia Pacific
  • 6.4.4. Latin America
  • 6.4.5. Middle East and Africa
• 6.5. SWOT Analysis by Factor (Political & Legal, Economic and Technological)
  • 6.5.1. North America
  • 6.5.2. Europe
  • 6.5.3. Asia Pacific
  • 6.5.4. Latin America
  • 6.5.5. Middle East and Africa
• 6.6. Market Size, & Forecasts and Trend Analysis, 2022 to 2030:
• 6.7. North America
  • 6.7.1. U.S.
    • 6.7.1.1. Key Country Dynamics
    • 6.7.1.2. Regulatory Landscape/Reimbursement Scenario
    • 6.7.1.3. Competitive Landscape
    • 6.7.1.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 6.7.2. Canada
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Regulatory Landscape/Reimbursement Scenario
    • 6.7.2.3. Competitive Landscape
    • 6.7.2.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 6.7.3. Mexico
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Regulatory Landscape/Reimbursement Scenario
    • 6.7.3.3. Competitive Landscape
    • 6.7.3.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
• 6.8. Europe
  • 6.8.1. UK
    • 6.8.1.1. Key Country Dynamics
    • 6.8.1.2. Regulatory Landscape/Reimbursement Scenario
    • 6.8.1.3. Competitive Landscape
    • 6.8.1.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 6.8.2. Germany
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Regulatory Landscape/Reimbursement Scenario
    • 6.8.2.3. Competitive Landscape
    • 6.8.2.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 6.8.3. France
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Regulatory Landscape/Reimbursement Scenario
    • 6.8.3.3. Competitive Landscape
    • 6.8.3.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 6.8.4. Italy
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Regulatory Landscape/Reimbursement Scenario
    • 6.8.4.3. Competitive Landscape
    • 6.8.4.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 6.8.5. Spain
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Regulatory Landscape/Reimbursement Scenario
    • 6.8.5.3. Competitive Landscape
    • 6.8.5.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 6.8.6. Denmark
    • 6.8.6.1. Key Country Dynamics
    • 6.8.6.2. Regulatory Landscape/Reimbursement Scenario
    • 6.8.6.3. Competitive Landscape
    • 6.8.6.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 6.8.7. Sweden
    • 6.8.7.1. Key Country Dynamics
    • 6.8.7.2. Regulatory Landscape/Reimbursement Scenario
    • 6.8.7.3. Competitive Landscape
    • 6.8.7.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 6.8.8. Norway
    • 6.8.8.1. Key Country Dynamics
    • 6.8.8.2. Regulatory Landscape/Reimbursement Scenario
    • 6.8.8.3. Competitive Landscape
    • 6.8.8.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
• 6.9. Asia Pacific
  • 6.9.1. Japan
    • 6.9.1.1. Key Country Dynamics
    • 6.9.1.2. Regulatory Landscape/Reimbursement Scenario
    • 6.9.1.3. Competitive Landscape
    • 6.9.1.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 6.9.2. China
    • 6.9.2.1. Key Country Dynamics
    • 6.9.2.2. Regulatory Landscape/Reimbursement Scenario
    • 6.9.2.3. Competitive Landscape
    • 6.9.2.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 6.9.3. India
    • 6.9.3.1. Key Country Dynamics
    • 6.9.3.2. Regulatory Landscape/Reimbursement Scenario
    • 6.9.3.3. Competitive Landscape
    • 6.9.3.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 6.9.4. South Korea
    • 6.9.4.1. Key Country Dynamics
    • 6.9.4.2. Regulatory Landscape/Reimbursement Scenario
    • 6.9.4.3. Competitive Landscape
    • 6.9.4.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 6.9.5. Thailand
    • 6.9.5.1. Key Country Dynamics
    • 6.9.5.2. Regulatory Landscape/Reimbursement Scenario
    • 6.9.5.3. Competitive Landscape
    • 6.9.5.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 6.9.6. Australia
    • 6.9.6.1. Key Country Dynamics
    • 6.9.6.2. Regulatory Landscape/Reimbursement Scenario
    • 6.9.6.3. Competitive Landscape
    • 6.9.6.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
• 6.10. Latin America
  • 6.10.1. Brazil
    • 6.10.1.1. Key Country Dynamics
    • 6.10.1.2. Regulatory Landscape/Reimbursement Scenario
    • 6.10.1.3. Competitive Landscape
    • 6.10.1.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 6.10.2. Argentina
    • 6.10.2.1. Key Country Dynamics
    • 6.10.2.2. Regulatory Landscape/Reimbursement Scenario
    • 6.10.2.3. Competitive Landscape
    • 6.10.2.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
• 6.11. MEA
  • 6.11.1. South Africa
    • 6.11.1.1. Key Country Dynamics
    • 6.11.1.2. Regulatory Landscape/Reimbursement Scenario
    • 6.11.1.3. Competitive Landscape
    • 6.11.1.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 6.11.2. Saudi Arabia
    • 6.11.2.1. Key Country Dynamics
    • 6.11.2.2. Regulatory Landscape/Reimbursement Scenario
    • 6.11.2.3. Competitive Landscape
    • 6.11.2.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 6.11.3. UAE
    • 6.11.3.1. Key Country Dynamics
    • 6.11.3.2. Regulatory Landscape/Reimbursement Scenario
    • 6.11.3.3. Competitive Landscape
    • 6.11.3.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 6.11.4. Kuwait
    • 6.11.4.1. Key Country Dynamics
    • 6.11.4.2. Regulatory Landscape/Reimbursement Scenario
    • 6.11.4.3. Competitive Landscape
    • 6.11.4.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competitive Categorization
  • 7.2.1. Innovators
  • 7.2.2. Market leaders
  • 7.2.3. Emerging players
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2024
• 7.4. Public Companies
  • 7.4.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
  • 7.4.2. Company market share/ranking, by region
  • 7.4.3. Competitive dashboard analysis
    • 7.4.3.1. Market differentiators
    • 7.4.3.2. Synergy analysis: major deals and strategic alliances
• 7.5. Private Companies
  • 7.5.1. List of key emerging companies/technology disruptors/innovators
  • 7.5.2. Funding outlook
  • 7.5.3. Regional network map
  • 7.5.4. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)
  • 7.5.5. Supplier ranking
  • 7.5.6. Key company profiled
  • 7.5.7. Eigen
    • 7.5.7.1. Company overview
    • 7.5.7.2. Financial performance
    • 7.5.7.3. Product benchmarking
    • 7.5.7.4. Strategic initiatives
  • 7.5.8. Koninklijke Philips N.V.
    • 7.5.8.1. Company overview
    • 7.5.8.2. Financial performance
    • 7.5.8.3. Product benchmarking
    • 7.5.8.4. Strategic initiatives
  • 7.5.9. Hitachi, Ltd.
    • 7.5.9.1. Company overview
    • 7.5.9.2. Financial performance
    • 7.5.9.3. Product benchmarking
    • 7.5.9.4. Strategic initiatives
  • 7.5.10. MedCom
    • 7.5.10.1. Company overview
    • 7.5.10.2. Financial performance
    • 7.5.10.3. Product benchmarking
    • 7.5.10.4. Strategic initiatives
  • 7.5.11. ESAOTE SPA
    • 7.5.11.1. Company overview
    • 7.5.11.2. Financial performance
    • 7.5.11.3. Product benchmarking
    • 7.5.11.4. Strategic initiatives
  • 7.5.12. KOELIS
    • 7.5.12.1. Company overview
    • 7.5.12.2. Financial performance
    • 7.5.12.3. Product benchmarking
    • 7.5.12.4. Strategic initiatives
  • 7.5.13. Focal Healthcare
    • 7.5.13.1. Company overview
    • 7.5.13.2. Financial performance
    • 7.5.13.3. Product benchmarking
    • 7.5.13.4. Strategic initiatives
  • 7.5.14. GeoScan Medical
    • 7.5.14.1. Company overview
    • 7.5.14.2. Financial performance
    • 7.5.14.3. Product benchmarking
    • 7.5.14.4. Strategic initiatives
  • 7.5.15. UC-Care Medical Systems Ltd.
    • 7.5.15.1. Company overview
    • 7.5.15.2. Financial performance
    • 7.5.15.3. Product benchmarking
    • 7.5.15.4. Strategic initiatives